Health Care • Biotechnology: Pharmaceutical Preparations
$6.63 ▲ +0.40
(+6.42%)
MKT CAP: $385.5M • VOL: 3.33M
52W L $3 52W H $40
CAPR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $22.3M | $25.2M |
| YoY Revenue Growth % | — | -11.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$108.1M | -$42.6M | -$24.1M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$105.0M | -$40.5M | -$22.3M |
| EBITDA (Normalized) | -$105.8M | -$41.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$69.8M | -$40.0M | -$25.6M |
| Capital Expenditures (CapEx) | $2.9M | $1.2M | — |
| Free Cash Flow (FCF) | -$72.7M | -$41.2M | -$25.6M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -25.1% | — |
| Cash & Short-Term Equivalents | $287.8M | $11.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $305.8M | $145.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CAPR.